

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.

OMB APPROVAL


OMB Number: 3235-0076

Expires: August 31, 2015

Estimated Average burden hours per response: 4.0

1. Issuer's Identity			
CIK (Filer ID Number)	Previous Name(s)	▼ None	Entity Type
0001372514			• Corporation
Name of Issuer			C Limited Partnership
EYEGATE PHARMACEUTICALS INC			C Limited Liability Company
Jurisdiction of Incorporation/Organization	_		General Partnership
DELAWARE			O Business Trust
Year of Incorporation/Organization	n		Other
Over Five Years Ago			
O Within Last Five Years (Specify Year)			
O Yet to Be Formed			

2. Principal Place of Business and Contact Information Name of Issuer EYEGATE PHARMACEUTICALS INC Street Address 1 Street Address 2 271 WAVERLEY OAKS ROAD City State/Province/Country ZIP/Postal Code Phone No. of Issuer WALTHAM MASSACHUSETTS 02452 781-788-9043



Relationship:	Execu	tive Officer	Director		Promoter	
Clarification of Response	e (if Necessary	y)				
Chief Financial Officer						
Last Name		First Name		Middle 1	Name	
Malfroy-Camine		Bernard				
Street Address 1			Street Address 2	2		
271 Waverley Oaks I	Road, Suite 1	08				
City State/P		State/Province	e/Province/Country		tal Code	
Waltham	ham MASSACHUSETTS		02452			
Relationship:	Execu	tive Officer	Director		Promoter	
Clarification of Response	e (if Necessary	y)				
_						
Last Name		First Name		Middle 1	Name	
Chaney		Paul				
Street Address 1			Street Address 2	2		
271 Waverley Oaks I	Road, Suite 1	08				
City		State/Province	c/Country	ZIP/Pos	tal Code	
Waltham		MASSACHU	JSETTS	02452		
Relationship:	Execu	tive Officer	Director		Promoter	
Clarification of Response	e (if Necessary	v)				
•						
Last Name		First Name		Middle	Name	
Boyd		Steven				
Street Address 1			Street Address 2	2		
271 Waverley Oaks I	Road, Suite 1	08				
City			c/Country	ZIP/Pos	ZIP/Postal Code	
Waltham		MASSACHU	JSETTS	02452	02452	
	·					
Relationship:	Execu	tive Officer	Director		Promoter	
	4037					
Clarification of Response	e (if Necessary	y)				
Last Nama		First Name		M:JJI.	Nama	
Last Name	1	First Name		Middle	valle	
Goldberg Street Address 1		Morton	Stuant A January	<u> </u>		
Street Address 1	Pood Suit- 1	00	Street Address 2			
271 Waverley Oaks I	xoau, Suite 1		(6	ZID.	4.1.01	
City		State/Province			tal Code	
Waltham		MASSACHU	JSETTS	02452		
	_				- ·	
Relationship:	Execu	tive Officer	Director		Promoter	

Last Name	First Name	Middle Name		
Tyle	Praveen			
Street Address 1	Street Address	s 2		
271 Waverley Oaks Road, Suite	108			
City	State/Province/Country	ZIP/Postal Code		
Waltham	MASSACHUSETTS	02452		
Relationship: Exec	eutive Officer	Promoter		
		<u> </u>		
Clarification of Response (if Necessa	ry)			
ast Name First Name		Middle Name		
Hancock	Thomas			
Street Address 1	Street Address	s 2		
271 Waverley Oaks Road, Suite	108			
City	State/Province/Country	ZIP/Postal Code		
Waltham	MASSACHUSETTS	02452		
Dalatianskin.	eutive Officer	Promoter		
Relationship: Exec	utive Officer Director	Promoter		
Maher	First Name Keith			
Street Address 1	Street Address	s 2		
271 Waverley Oaks Road, Suite	108			
City	State/Province/Country	ZIP/Postal Code		
Waltham	MASSACHUSETTS	02452		
Relationship: Exec	eutive Officer Director	Promoter		
r L	<u>II.</u> <u>Birotor</u>	1		
Clarification of Response (if Necessa	ry)			
1 Industry Craws				
1. Industry Group				
Agriculture	Health Core			
U Agriculture	Health Care O Biotechnology	C Retailing		
Banking & Financial Services	7.40	C Restaurants		
590	C Biotechnology	© Restaurants		
Banking & Financial Services	C Biotechnology C Health Insurance C Hospitals & Physicians Pharmaceuticals	© Restaurants Technology		
Banking & Financial Services Commercial Banking Insurance Investing	C Biotechnology C Health Insurance C Hospitals & Physicians	C Restaurants Technology Computers		
Banking & Financial Services Commercial Banking Insurance Investing Investment Banking	C Biotechnology C Health Insurance C Hospitals & Physicians Pharmaceuticals	C Restaurants Technology Computers Telecommunications		
Banking & Financial Services Commercial Banking Insurance Investing Investment Banking Pooled Investment Fund	C Biotechnology C Health Insurance C Hospitals & Physicians Pharmaceuticals	C Restaurants Technology Computers		
Banking & Financial Services Commercial Banking Insurance Investing Investment Banking Pooled Investment Fund Other Banking & Financial	C Biotechnology C Health Insurance C Hospitals & Physicians Pharmaceuticals C Other Health Care	C Restaurants Technology Computers Telecommunications		
Banking & Financial Services Commercial Banking Insurance Investing Investment Banking Pooled Investment Fund Other Banking & Financial Services	C Biotechnology C Health Insurance C Hospitals & Physicians Pharmaceuticals C Other Health Care C Manufacturing	C Restaurants Technology Computers Telecommunications Other Technology		
Banking & Financial Services Commercial Banking Insurance Investing Investment Banking Pooled Investment Fund Other Banking & Financial	C Biotechnology C Health Insurance C Hospitals & Physicians Pharmaceuticals C Other Health Care	C Restaurants Technology Computers C Telecommunications C Other Technology Travel		

C REITS & Finance

C Residential

Other Real Estate

C Electric Utilities

C Oil & Gas
C Other Energy

C Energy Conservation

C Environmental Services

C Other Travel

C Other

5. Issuer Size	
Revenue Range	Aggregate Net Asset Value Range
C No Revenues	C No Aggregate Net Asset Value
C \$1 - \$1,000,000	C \$1 - \$5,000,000
\$1,000,001 - \$5,000,000	\$5,000,001 - \$25,000,000
\$5,000,001 - \$25,000,000	\$25,000,001 - \$50,000,000
\$25,000,001 - \$100,000,000	\$50,000,001 - \$100,000,000
Over \$100,000,000	Over \$100,000,000
• Decline to Disclose	C Decline to Disclose
C Not Applicable	C Not Applicable
6. Federal Exemption apply)	(s) and Exclusion(s) Claimed (select all that
Rule 504(b)(1) (not (i), (ii) or (iii))	Rule 505
Rule 504 (b)(1)(i)	▼ Rule 506(b)
Rule 504 (b)(1)(ii)	
	Rule 506(c)
Rule 504 (b)(1)(iii)	Securities Act Section 4(a)(5)
	Investment Company Act Section 3(c)
New Notice Date of First S Amendment	Sale 2021-01-06 First Sale Yet to Occur
Amendment 8. Duration of Offering	First Sale Yet to Occur
Amendment 8. Duration of Offering 9. Type(s) of Securities Pooled Investment Fund Interests Tenant-in-Common Securities Mineral Property Securities Security to be Acquired Upon Exercise of Ontion Warrant or	First Sale Yet to Occur
Amendment 8. Duration of Offering 9. Type(s) of Securitie Pooled Investment Fund Interests Tenant-in-Common Securities Mineral Property Securities Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire	last more than one year? Solution Solution Print Sale Yet to Occur Print Sale Yet to Occur Yes No Solution Solution Print Sale Yet to Occur No No Solution Solution Solution Solution Solution Solution Transaction Solution Solution Transaction Solution Solution Solution Transaction Solution Solution Transaction Solution Soluti

Recipient	Recipient CRD Number	None
(Associated) Broker or Dealer None	(Associated) Broker or Dealer Number	CRD None
Street Address 1	Street Address 2	
City	State/Province/Country	ZIP/Postal Code
State(s) of Solicitation	☐ All States	
10.0%		
13. Offering and Sales Amoun	ts	
Total Offering Amount \$ 8000003	USD ☐ Indefinite	
Total Amount Sold \$ 8000003	USD	
Total Remaining to be \$ 0	USD Indefinite	
Clarification of Response (if Necessary)		
(if the sponso (if th		
14. Investors		
Select if securities in the offering have bee do not qualify as accredited investors, Number of such non-accredited investors offering Regardless of whether securities in the off to persons who do not qualify as accredite	who already have invested in the ering have been or may be sold dinvestors, enter the total	
number of investors who already have inv	ested in the offering:	
15. Sales Commissions & Find	lers' Fees Expenses	
Provide separately the amounts of sales commission expenditure is not known, provide an estimate and o	1 , ,	e amount of an
Sales Commissions \$ 0	USD E	stimate
Finders' Fees \$ 0	USD E	stimate
Clarification of Response (if Necessary)		
		1
16. Use of Proceeds		
Provide the amount of the gross proceeds of the offe any of the persons required to be named as executiv If the amount is unknown, provide an estimate and	e officers, directors or promoters in res	
\$	0 USD	Estimate
Clarification of Response (if Necessary)		
Some of the proceeds may be used for working capital and other general corporate purposes, which may include the payment of salaries		

and other fees to those listed in Item
3.

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each Issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities
 described and undertaking to furnish them, upon written request, the information furnished to
 offerees
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the Issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against it in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Regulation D for one of the reasons stated in Rule 505(b)(2)(iii) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
EYEGATE PHARMACEUTIC. INC	ALS /s/ Sarah Roman	o Sarah Romano	Chief Financial Officer	2021-01-21